XOMA Royalty (XOMA) Cash & Equivalents (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Cash & Equivalents came in at $85.6 million in Q1 2026, up 1367.76% year-on-year from $5.8 million in Q1 2025, and up 3.25% quarter-over-quarter from $82.9 million in Q4 2025.
XOMA Royalty (XOMA) Cash & Equivalents (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Cash & Equivalents across 17 years of filings, most recently posting $85.6 million for Q1 2026.
- Cash & Equivalents for Q1 2026 came in at $85.6 million, up 1367.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $85.6 million (up 1367.76% YoY), and the FY2025 annual result was $82.9 million, up 822.94% from the prior year.
- Cash & Equivalents came in at $85.6 million for Q1 2026 at XOMA Royalty, up from $82.9 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $153.3 million in Q4 2023 to a low of $4.0 million in Q3 2024.
- The 5-year median for Cash & Equivalents is $33.5 million (2023), against an average of $57.6 million.
- Across the five-year window, Cash & Equivalents plunged 95.72% in 2025 and soared 1367.76% in 2026, its largest moves.
- XOMA Royalty's Cash & Equivalents stood at $30.3 million in 2022, then soared by 405.91% to $153.3 million in 2023, then slumped by 94.14% to $9.0 million in 2024, then surged by 822.94% to $82.9 million in 2025, then gained by 3.25% to $85.6 million in 2026.
- The last three Cash & Equivalents figures came in at $85.6 million (Q1 2026), $82.9 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 558.94 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 85.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85.60 Mn |
| Dec 31, 2025 | 82.91 Mn |
| Sep 30, 2025 | 10.18 Mn |
| Jun 30, 2025 | 6.99 Mn |
| Mar 31, 2025 | 5.83 Mn |
| Dec 31, 2024 | 8.98 Mn |
| Sep 30, 2024 | 4.02 Mn |
| Jun 30, 2024 | 143.90 Mn |
| Mar 31, 2024 | 136.23 Mn |
| Dec 31, 2023 | 153.29 Mn |
| Sep 30, 2023 | 33.47 Mn |
| Jun 30, 2023 | 31.40 Mn |
| Mar 31, 2023 | 44.30 Mn |
| Dec 31, 2022 | 30.30 Mn |
| Sep 30, 2022 | 30.20 Mn |
| Jun 30, 2022 | 83.18 Mn |
| Mar 31, 2022 | 87.80 Mn |
| Dec 31, 2021 | 93.33 Mn |
| Sep 30, 2021 | 68.76 Mn |
| Jun 30, 2021 | 78.95 Mn |